Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy
- 15 January 2004
- journal article
- Published by Springer Nature in Oncogene
- Vol. 23 (2) , 418-425
- https://doi.org/10.1038/sj.onc.1207042
Abstract
The p53 oncosuppressor is strictly maintained in an inactive form under normal conditions, while it is post-translationally activated by a variety of stresses, enacting different protective biological functions. Since one critical issue in cancer gene therapy is tumor specificity, we asked whether the tight p53 regulation applies also to exogenously transferred p53. In principle, this type of regulation could allow p53 gene transfer in both normal and tumor cells to produce detrimental effects only in the latter ones. Here, we report that primary bone marrow cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, with no detectable alterations in any of its compartments. Furthermore, simultaneous infection of leukemia and bone marrow cells depleted the neoplastic contamination, allowing lifelong, disease-free survival of 65% of the transplanted animals. These results show that exogenous p53 is controlled as tightly as the endogenous one, and opens the way to p53 gene therapy, without requiring tumor targeting.Keywords
This publication has 27 references indexed in Scilit:
- Gene Therapy 2000Hematology-American Society Hematology Education Program, 2000
- Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targetingThe Journal of Gene Medicine, 2000
- Development of a murine orthotopic model of leukemia: Evaluation of TP53 gene therapy efficacyCancer Gene Therapy, 2000
- The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cellsOncogene, 1999
- Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapyGene Therapy, 1998
- Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cellsOncogene, 1997
- Gene-marking and haemopoietic stem-cell transplantationBlood Reviews, 1995
- Safety Evaluation of Ad5CMY-p53 In VitroandIn VivoHuman Gene Therapy, 1995
- The Moral TalesHispania, 1989
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989